Roche

Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance.

"We are proud to be again designated Supersector leader in healthcare in the Dow Jones Sustainability Index. This top ranking is a reflection of Roche's commitment to its employees, communities and the environment. Sustainable corporate policies and practices ultimately create long-term value for our stakeholders and promote innovation," said Severin Schwan, CEO of Roche. "Over the past year we have made progress on our diversity and energy goals as well as introduced new programmes to increase access to our products in developing countries. Our ongoing leadership position will further encourage us to drive these programmes while continuing to discover and develop innovative medicines and diagnostic solutions for patients with unmet medical needs."

Some of Roche's efforts emphasized in this year's DJSI assessment were Roche's programmes focused on attracting and retaining talent, developing future leaders as well as environmental management and reporting. In addition, managing innovation along with our contribution to improving patient health outcomes was highlighted.

In 2009 Roche defined five-year corporate goals, with Key Performance Indicators enabling it to measure the progress. Amongst them, Roche introduced a diversity objective to increase the percentage of women in key positions by at least 50 percent, plus an energy efficiency goal of a 10 percent reduction in energy consumption by end 2014.

About the Dow Jones Sustainability Indexes (DJSI)
The DJSI is the most widely accepted global assessment of how companies approach their social, economic and environmental responsibility. Annual selection into the DJSI World and DJSI Europe follows a thorough analysis of corporate economic, environmental and social performance by Sustainable Asset Management (SAM), an investment specialist group focused exclusively on sustainability investment strategies. They assess business management practices such as corporate governance, risk management, human resource practices, customer relations, stakeholder engagement and the quality of environmental reporting, in addition to sector-specific elements, such as strategies on access to medicines and innovation in R&D. Roche has been included in the DJSI World and Europe since 2004, and was named Supersector Leader in healthcare in 2009 and again in 2010.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

One family's history of the rare co…

In recognition of International Fabry Awareness month, Shire has released the trailer for Our Fabry Family Tree, a short film series featuring a family who were unknowing...

Read more

What's the secret to living a full …

If you have ever asked yourself, "What makes me feel most fulfilled?" you are not alone. Nearly 2 million people recently answered that question in a new survey by Abbott...

Read more

Bristol-Myers Squibb reports first …

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo, Eliquis and our hepatitis...

Read more

Researchers discover potential trea…

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that lead...

Read more

Bayer off to a successful start in …

The Bayer Group got off to a successful start in the new fiscal year. "All segments posted gains in their operating performance," said CEO Dr. Marijn Dekkers when he pres...

Read more

Ready. Raise. Rise. Campaign

The Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and le...

Read more

Pfizer reports first-quarter 2016 r…

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2016 and updated certain components of its 2016 financial guidance. Reported revenues totaled $13.0 b...

Read more

Research points to a new treatment …

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously ...

Read more

'Mediterranean' diet linked to lowe…

A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease...

Read more

Merck brings international start-up…

Merck, a leading science and technology company, has announced the participants for its Accelerator Programs in Darmstadt and Nairobi. Almost 200 highly competitive appli...

Read more

AstraZeneca completes acquisition o…

AstraZeneca has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015...

Read more

Why are women less likely to be pre…

Statins are equally effective at decreasing risk of coronary events in men and women, and yet women are less likely to be prescribed these cholesterol-lowering drugs than...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]